Berard, EmilieRöllig, ChristophBertoli, SarahPigneux, ArnaudTavitian, SuzanneKramer, MichaelServe, HubertBornhäuser, MartinPlatzbecker, UweMüller-Tidow, CarstenBaldus, Claudia DMartinez-Cuadron, DavidSerrano, JosefinaMartinez-Sanchez, PilarArboli, Eduardo RodriguezGil, CristinaBergua, JuanBernal, Teresade la Fuente Burguera, AdolfoDelabesse, EricBidet, AudreyDumas, Pierre-YvesMontesinos, PauRecher, Christian2023-05-032023-05-032022-06-22Bérard E, Röllig C, Bertoli S, Pigneux A, Tavitian S, Kramer M, et al. A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries. Blood Cancer J. 2022 Jul 11;12(7):10http://hdl.handle.net/10668/19518In a context of therapeutic revolution in older adults with AML, it is becoming increasingly important to select patients for the various treatment options by taking account of short-term efficacy and toxicity as well as long-term survival. Here, the data from three European registries for 1,199 AML patients aged 70 years or older treated with intensive chemotherapy were used to develop a prognostic scoring system. The median follow-up was 50.8 months. In the training set of 636 patients, age, performance status, secondary AML, leukocytosis, and cytogenetics, as well as NPM1 mutations (without FLT3-ITD), were all significantly associated with overall survival, albeit not to the same degree. These factors were used to develop a score that predicts long-term overall survival. Three risk-groups were identified: a lower, intermediate and higher-risk score with predicted 5-year overall survival (OS) probabilities of ≥12% (n = 283, 51%; median OS = 18 months), 3-12% (n = 226, 41%; median OS = 9 months) and <3% (n = 47, 8%; median OS = 3 months), respectively. This scoring system was also significantly associated with complete remission, early death and relapse-free survival; performed similarly in the external validation cohort (n = 563) and showed a lower false-positive rate than previously published scores. The European Scoring System ≥70, easy for routine calculation, predicts long-term survival in older AML patients considered for intensive chemotherapy.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/Leukemia, myeloid, acuteMutationNeoplasm recurrence, localNuclear proteinsAgedHumansNucleophosminPrognosisRegistriesresearch article35821023open accessAncianoHumanosNucleofosminaPronósticoSistema de registros10.1038/s41408-022-00700-x2044-5385PMC9276717https://www.nature.com/articles/s41408-022-00700-x.pdfhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC9276717/pdf